RecruitingNot applicableNCT06682442

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Studying Epstein-Barr Virus-associated carcinoma

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of California, San Francisco
Principal Investigator: Sue Yom, MD, PhD
University of California, San Francisco
Intervention: Intensity-Modulated Radiation Therapy (IMRT)(radiation)
Enrollment: 66 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2032

Study locations (1)

University of California, San Francisco, San Francisco, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06682442 on ClinicalTrials.gov

Other trials for Epstein-Barr Virus-associated carcinoma

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT04925544
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University

See all trials for Epstein-Barr Virus-associated carcinoma →

← Back to all trials